Every 8-K that Aspire-Lakewood Holdings, Inc. Warrant (ASBPW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ASBPW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASBPW filings page.
Aspire-Lakewood Holdings, Inc. (ASBP) completed its acquisition of Dura Driver Control Systems (DCS) on August 6, 2026, for approximately $30 million. A five-year management services agreement with Lakewood Capital, LLC became effective at closing.
Aspire-Lakewood will pay Lakewood a $500,000 closing fee and reimburse closing expenses up to $200,000. Annual management fees equal 5% of Adjusted EBITDA, capped at $1 million. Lakewood is to receive 15% of DCSC equity within 10 days of closing, vesting monthly over two years and estimated at approximately $4.5 million based on the purchase price. The put option cannot be exercised during the first two years after closing; afterward, Lakewood may sell up to 5% of DCSC equity in any 12-month period with 90 days' notice, at a valuation applying a 15% discount to implied equity value after debt.
DCS reported 2025 revenue of $208.852 million and net income of $9.782 million, compared with $205.397 million revenue and $22.816 million net income in 2024. For the six months ended June 30, 2026, DCS reported revenue of $103.788 million and a net loss of $727,000, compared with $103.291 million revenue and $12.196 million net income in the 2025 period.
ASBP disclosed that its Audit Committee dismissed Turner Stone & Company, LLP as independent registered public accounting firm effective September 24, 2026, and approved CBIZ CPAs P.C. as the new independent auditor for the fiscal year ending December 31, 2026, effective immediately.
Turner’s report on the financial statements as of December 31, 2025 did not contain an adverse or disclaimer opinion and was not qualified or modified, except for an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern. Management concluded that disclosure controls and procedures were ineffective as of December 31, 2025 due to material weaknesses in internal control over financial reporting. The company reported no disagreements with Turner during 2025 or the subsequent interim periods through September 24, 2026.
Aspire Biopharma Holdings, Inc. (ASBP), now renamed Aspire-Lakewood Holdings, Inc., amended its Delaware charter to effect a corporate name change effective September 8, 2026; the Nasdaq listing, ticker and CUSIP remain the same and stockholders do not need to take any action.
The company’s board also authorized a $10 million common stock repurchase program effective September 9, 2026. Aspire-Lakewood highlights its newly acquired subsidiary, Dura Control Systems Corp. (DCSC), which generated 2025 revenue of about $209.5 million and Adjusted EBITDA of $22.3 million, and revenue of about $103.9 million and Adjusted EBITDA of $10.5 million for the six months ended June 30, 2026. With roughly 1.5 million common shares outstanding as of September 8, 2026, management views the repurchase authorization as an opportunistic use of capital, while noting repurchases may vary or be suspended based on conditions.
Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) reported that it has changed its corporate name to Aspire-Lakewood Holdings, Inc., effective upon filing a Certificate of Amendment to its Certificate of Incorporation with the Delaware Secretary of State. The company’s common stock will continue to trade on The Nasdaq Capital Market under the same ticker symbol, and existing stock certificates remain valid.
The name change, approved by the board and stockholders under Section 242 of the Delaware General Corporation Law, is positioned as aligning the company’s holding company structure with its expanded focus following the acquisition of Dura Control Systems Corp. (DCSC), a designer and manufacturer of engineered automotive and industrial control systems. The change does not alter stockholder rights or require any action by stockholders.
Aspire Biopharma Holdings, Inc. (ASBP) reported that it plans to distribute an investor presentation on August 19, 2026. The company furnished this presentation as Exhibit 99.1 to provide additional information to the market under a Regulation FD disclosure.
The common stock and public warrants of Aspire Biopharma Holdings, Inc. trade on The Nasdaq Stock Market LLC under the symbols ASBP and ASBPW, respectively. The report was authorized on behalf of the company by Chief Executive Officer Kraig Higginson.
Aspire Biopharma Holdings, Inc. completed the acquisition of Dura Driver Control Systems (DCS), purchasing 100% of DCS’s shares for approximately $30.0 million in cash. DCS, a tier-one automotive systems supplier, becomes a wholly owned subsidiary and is expected to enhance Aspire’s revenue, earnings and cash flow profile.
DCS generated unaudited revenue of $209.5 million and Adjusted EBITDA of $22.3 million in 2025, and revenue of $103.9 million and Adjusted EBITDA of $10.5 million for the six months ended June 30, 2026. Aspire entered into a $22.5 million senior secured revolving credit facility to help fund the acquisition alongside cash on hand.
The board also approved and the company issued convertible promissory notes with an aggregate principal of $3,750,000, sold for $3,000,000 (a 20% original issue discount), intended for working capital and future growth opportunities. These notes are convertible into common stock at a $8.00 per-share conversion price and were issued in a private offering relying on Section 4(a)(2) and Rule 506(b) exemptions.
Aspire Biopharma Holdings, Inc. clarified the current terms of its Nasdaq-listed public warrants, which trade under the symbol ASBPW, following requests from warrant holders. The warrants were originally issued on February 23, 2022 in connection with the initial public offering of its predecessor, Power Up Acquisition Corp.
The warrants initially had an exercise price of $11.50 per share, subject to adjustment for events such as share consolidations. After a 1-for-30 reverse stock split on January 16, 2026 and an additional 40-for-1 reverse split on May 11, 2026, each public warrant now carries an exercise price of $13,800 per share and a ratio of 1,200 warrants to purchase one share of common stock.
Aspire Biopharma Holdings, Inc. held a Special Meeting of Stockholders on June 16, 2026, where stockholders constituting a quorum voted on several matters. The filing shows that each proposal received strong support, with the first proposal receiving 1,742,683 votes for, 107,523 against, and 4,818 abstentions, and no broker non-votes. Two additional proposals also passed with similar levels of support, including one with 1,745,709 votes for and another with 1,739,702 votes for, and no broker non-votes in any case. The company remains listed on The Nasdaq Stock Market LLC under the symbols ASBP for its common stock and ASBPW for its warrants.
Aspire Biopharma Holdings, Inc. reported that its shareholder meeting held on June 9, 2026 was adjourned because a quorum was not reached. The company has rescheduled the meeting to June 16, 2026 at 10:00 a.m. EST. The online access link remains www.colonialstock.com/AspireBiopharma2026.
Aspire Biopharma Holdings, Inc. entered into a definitive purchase agreement to acquire 100% of Dura Driver Control Systems for a cash purchase price of $30 million. The deal covers all equity interests in specified subsidiaries and assets that make up DCS’s driver control systems business.
The closing price will be adjusted to reflect an $800,000 credit for deferred revenue, income tax items, and indebtedness at closing. A key condition is that Sellers must deliver a PCAOB audit for 2024 and 2025 with an unqualified opinion and at least $12 million of gross profit minus capital expenditures, or Aspire can terminate after the September 10, 2026 outside date.
DCS generated more than $200 million in 2025 revenue, over $17 million in net income, and more than $22 million in Adjusted EBITDA. Either party may terminate under specified conditions, and in certain cases a one-time $3.5 million termination fee is payable. Aspire states it does not expect to raise new equity to fund the transaction.
Aspire Biopharma Holdings, Inc. approved a major change to its capital structure by amending its Certificate of Incorporation to implement a 1-for-30 reverse stock split of its issued and outstanding common stock. This means every thirty existing shares will be automatically combined into one new share when the change becomes effective.
No fractional shares will be issued; any resulting fraction will be rounded up to the nearest whole share, slightly increasing some holders’ share counts. The company’s common stock will continue trading on the Nasdaq Stock Market, with the trading symbol remaining “ABSP,” while the common stock will receive a new CUSIP number.
Aspire Biopharma Holdings, Inc. closed a $21.0 million private placement and strengthened its balance sheet while pursuing a major acquisition. The company completed the second and final tranche of its Series A Convertible Preferred Stock financing, issuing 12,500 shares for $10.0 million, bringing total proceeds to $21.0 million and lifting stockholders’ equity above the $2.5 million Nasdaq Capital Market minimum. Aspire plans to use the cash for working capital, to help fund the proposed acquisition of Dura Control Systems (DCS), and for general corporate purposes. It has a Letter of Intent to buy 100% of DCS, which generated more than $20 million in Adjusted EBITDA on over $200 million of 2025 revenue, for a $30 million all-cash purchase price. To finance this, Aspire obtained a commitment letter for a senior secured credit facility of up to $22.5 million on a five-year term at an interest rate 325 basis points above the one‑month term Secured Overnight Financing Rate.
Aspire Biopharma Holdings, Inc. completed a private placement Offering of 25,000 shares of Series A Convertible Preferred Stock for gross proceeds of about $21,000,000, split across two tranches. The first tranche closed on February 6, 2026 for 13,750 shares and $11,000,000, including conversion of $943,801 of existing debt.
On April 15, 2026, the company closed the second tranche for 12,500 shares and approximately $10,000,000 in gross proceeds. Net proceeds are intended to fund the cash component of a proposed Dura Driver Control Systems acquisition and for general corporate purposes. The company also filed a Certificate of Amendment designating 30,000 shares of Series A Convertible Preferred Stock with a par value of $0.0001 and stated value of $1,000 per share.
Aspire Biopharma Holdings, Inc. completed a private Offering of Series A Convertible Preferred Stock and amended the terms of this preferred class. The company has now issued 13,750 preferred shares for gross proceeds of $11,000,000 at the initial closing and an additional 12,500 preferred shares for $10,000,000 at a second closing on April 15, 2026.
Each preferred share has a stated value of $1,000 and is convertible into common stock at a price equal to 80% of the lowest closing price over five recent trading days, but not below a floor equal to 20% of the Nasdaq “Minimum Price,” subject to adjustments. Conversions are capped so that an investor generally cannot beneficially own more than 4.99% of outstanding common stock, adjustable up to 9.99% with notice.
The Certificate of Designation was amended on April 13, 2026 to designate 30,000 Series A preferred shares. Aspire states that, as a result of the Offering, it believes stockholders’ equity now exceeds $2.5 million, meeting the minimum requirement for continued listing on The Nasdaq Capital Market, and it awaits Nasdaq’s formal confirmation.
Aspire Biopharma Holdings, Inc. held a Special Meeting of Stockholders on April 10, 2026, where a quorum of stockholders voted on several proposals. The 8-K reports that all matters presented at the meeting were approved based on the tabulated voting results.
The disclosed proposals received votes in favor ranging from 1,466,141 to 2,096,356, with varying levels of opposition, abstentions, and broker non-votes. The filing confirms the outcomes of these stockholder votes and is signed by Chief Executive Officer Kraig Higginson.
Aspire Biopharma Holdings, Inc. has signed a non-binding Letter of Intent to acquire Dura Driver Control Systems (DCS), a tier-one automotive and industrial systems supplier. Aspire expects to buy 100% of DCS for $30 million in cash, subject to due diligence and a definitive agreement.
For the fiscal year ended December 31, 2025 (unaudited), DCS generated more than $200 million in revenue, over $17 million in net income and over $22 million in Adjusted EBITDA. DCS supplies mechatronic actuators, human‑machine interfaces, industrial cables and control systems, backed by more than 310 patents and 11 manufacturing facilities worldwide.
The contemplated acquisition would diversify Aspire beyond biopharmaceutical drug delivery technology into a higher‑revenue industrial and automotive platform. The company cautions there is no assurance a definitive agreement will be finalized or that the transaction will close, and any deal would be subject to customary conditions and audited financials.
Aspire Biopharma Holdings, Inc. entered into a non-binding letter of intent to acquire 100% of the Driver Controls Systems business unit of Firefish Topco, LLC for an enterprise value of $30.0 million on a cash-free, debt-free basis, payable in cash at closing.
The LOI includes reciprocal break-up fees of $3.5 million under specified failure-to-close or bad-faith scenarios, as well as a 30-day no-shop period for the sellers, subject to possible extension. Most LOI terms are non-binding, and completion depends on negotiating and signing a definitive purchase agreement and satisfying closing conditions. Following a completed acquisition, the company plans to engage Lakewood & Company, LLC to provide management services for DCS, subject to a separate definitive management agreement.
Aspire Biopharma Holdings, Inc. entered into a securities purchase agreement for a private placement of up to 26,250 shares of Series A Convertible Preferred Stock at $800 per share, for potential gross proceeds of up to $21.0 million. The company completed an initial closing on February 6, 2026, issuing 13,750 preferred shares for $11.0 million, including the conversion of $943,801 of existing debt, and paying a $900,000 placement fee. A potential second closing of up to 12,500 additional preferred shares for up to $10,000,000 is conditioned on effectiveness of a resale registration statement and stockholder approval. Aspire believes the transaction has increased stockholders’ equity above the $2.5 million Nasdaq Capital Market requirement and plans a stockholder vote on the financing, a reverse stock split in a range of 1-for-5 to 1-for-500, and an increase in authorized shares. The filing also notes the resignation of director Donald G. Fell and the appointment of Philip Balatsos to the board, and grants the investors the right to appoint one director.
Aspire Biopharma Holdings, Inc. amended its charter to designate 25,000 shares of authorized preferred stock as Series A Convertible Non-Voting Preferred Stock. These shares are convertible into common stock at a price equal to 80% of the lowest closing price over the five trading days before conversion, subject to a floor equal to 20% of the Nasdaq “Minimum Price” and other adjustments.
Conversions are limited so that an investor generally cannot own more than 4.99% of outstanding common shares, with the option to increase this cap up to 9.99% on 61 days’ notice, and total issuances from conversion cannot exceed 19.99% of common shares outstanding without required shareholder approval. The Series A ranks senior to common stock on liquidation, has anti-dilution price protection, carries participation rights for up to 30% of certain future financings for six months, receives dividends on an as-converted basis when common stock receives non-stock dividends, and has no regular voting rights beyond those required by law or the charter.
Aspire Biopharma Holdings, Inc. entered into a Securities Purchase Agreement with certain investors, issuing debentures with an aggregate principal amount of $2,173,913.04 for a subscription price of $2,000,000. The debentures carry an 8% original issue discount, bear no annual interest, and mature on April 23, 2026, or sooner if the company receives at least $8,000,000 in gross proceeds from any equity or debt financing within 90 days. The debentures are not convertible into common stock, and the company may prepay them at par with ten business days’ notice. In connection with this financing, investors also received 790,000 shares of common stock as incentive shares. The company plans to use the proceeds to pay down debt and for working capital.